Pharmaceutical Raw Materials Skeletal Muscle Relaxant CAS 96946-42-8 Cisatracurium Besylate CAS NO.96946-42-8

1. Quick Detail:

Pharmaceutical Raw Materials Skeletal Muscle Relaxant CAS 96946-42-8 Cisatracurium Besylate
2. Description:

English name: Cisatracurium besilate
Alias: Cisatracurium besylate; Cisatracurium Besilete
CAS: 96946-42-8
Formula: C65H82N2O18S2
MW: 1243.47918
Molecular structure:


Appearance: white to pale yellow powder
Assay: 99% min

3. Description:

Cisatracurium (formerly recognized as 51W89,and marketed as Nimbex) is a neuromuscular-blocking drug or skeletal muscle relaxant in the category of non-depolarizing neuromuscular-blocking drugs, used adjunctively inanesthesia to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery ormechanical ventilation. It is a bisbenzyltetrahydroisoquinolinium agent with an intermediate duration of action. Cisatracurium is one of the ten isomers of the parent molecule, atracurium. Moreover, cisatracurium represents approximately 15% of the atracurium mixture.

4. Applications:

As is evident with the parent molecule, atracurium,cisatracurium is also susceptible to degradation by Hofmann elimination and ester hydrolysis as components of the in vivo metabolic processes.See the atracurium page for information on Hofmann elimination in vivo versus the Hofmann degradation chemical reaction.

Because Hofmann elimination is a temperature- and plasma pH-dependent process, cisatracurium's rate of degradation in vivo is highly influenced by body pH and temperature just as it is with the parent molecule, atracurium: thus, an increase in body pH favors the elimination process,whereas a decrease in temperature slows down the process.

One of the metabolites of cistracurium via Hofmann elimination is laudanosine - see the atracurium page for further discussion of the issue regarding this metabolite. 80% of cisatracurium is metabolized eventually to laudanosine and 20% is metabolized hepatically or excreted renally.^{[citation needed]} 10-15% of the dose is excreted unchanged in the urine.

Since Hofmann elimination is an organ-independent chemodegradative mechanism, there is little or no risk to the use of cisatracurium in patients with liver or renal disease when compared with other neuromuscular-blocking agents.

The two reverse ester linkages in the bridge between the two isoquinolinium groups make atracurium and cisatracurium poor targets for plasma cholinesterase, unlike mivacurium which has two conventional ester linkages.